Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361810 | 0.93 | BDKRB2 (0.66) | BDKRB2 | |
| SCHEMBL8367806 | 0.91 | BDKRB2 (0.68) | BDKRB2 | |
| SCHEMBL6580497 | 0.91 | BDKRB2 (0.57) | BDKRB2 | |
| SCHEMBL6581342 | 0.90 | BDKRB2 (0.56) | BDKRB2 | |
| SCHEMBL8361816 | 0.89 | BDKRB2 (0.68) | BDKRB2 | |
| SCHEMBL8367619 | 0.89 | BDKRB2 (0.61) | BDKRB2 | |
| SCHEMBL7747349 | 0.89 | BDKRB2 (0.55) | BDKRB2 | |
| SCHEMBL6578892 | 0.88 | BDKRB2 (0.57) | BDKRB2 | |
| SCHEMBL8361812 | 0.88 | BDKRB2 (0.67) | BDKRB2 | |
| SCHEMBL8361694 | 0.88 | BDKRB2 (0.79) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094899-B2 | Vitreous form of known bradykinin antagonist | ASTELLAS PHARMA INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-0807105-B1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20030120076-A1 | Vitreous form | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-0796848-B1 | Fluoralkyl- and fluoralkoxy-substituted heterocyclic bradykinin antagonists | HOECHST AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-6509468-B1 | FR 173657 used as an antiallergen, antiinflammatory agent, antishock agent, or analgesic; autoimmune diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-1123288-A1 | VITREOUS FORM OF KNOWN BRADYKININ ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| WO-2000023439-A1 | VITREOUS FORM OF KNOWN BRADYKININ ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-27 | — | — | WO | disclosed |
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0796848-A1 | Fluoralkyl- and fluoralkoxy-substituted heterocyclic bradykinin antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120076-A1 | Vitreous form | FAM162A, VEGFA, WEE2 | BDKRB2 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.